p53 but not p16(INK4a) induces growth arrest retinoblastoma-deficient hepatocellular carcinoma cells

Journal of Hepatology

Volumn 33, Issue 2, 2000, Pages 254-265

  Morel, Anne Pierre ^a   Unsal, Kezban ^b   Cagatay, Tolga ^b   Ponchel, Frederique ^a   Carr, Brian ^c   Ozturk, Mehmet ^a,b,d  

^a CENTRE LÉON BÉRARD   (France)

^b BILKENT UNIVERSITY   (Turkey)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d Dept Molec Biol Genet B   (Turkey)

Author keywords

Cell cycle arrest; Cyclin E; Hepatoma; p16(INK4a); p21(INK4a); p53; Retinoblastoma

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN E; PROTEIN BAX; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P53; CARRIER PROTEIN; PROTEIN P16INK4A; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE; CELL GROWTH; CYTOMETRY; EXPRESSION VECTOR; GENE FUNCTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPEROXIDASE STAINING; LIVER CELL CARCINOMA; MITOSIS INHIBITION; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RETINOBLASTOMA; TRANSACTIVATION; WESTERN BLOTTING; CELL CULTURE; CELL DIVISION; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; PATHOLOGY; TUMOR SUPPRESSOR GENE;

CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; LIVER NEOPLASMS; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED;

EID: 0033624329     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80366-9     Document Type: Article

References (35)

1. Strauss RM. Hepatocellular carcinoma: clinical, diagnostic, and therapeutic aspects. Rustgi AK. Gastrointestinal Cancers: Biology, Diagnosis and Therapy. 1995;479-496 Lippincott-Raven Publishers, Philadelphia.
2. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis. 19:1999;235-242.
3. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA. 87:1990;1973-1977.
4. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 350:1991;429-431.
5. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 350:1991;427-428.
6. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA. 91:1994;2230-2234.
7. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet. 9:1995;41-47.
8. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA. 94:1997;14707-14712.
9. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
10. Prives C. Signalling to p53: breaking the MDM2-p53 circuit. Cell. 95:1998;5-8.
11. Puisieux A, Ponchel F, Ozturk M. p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene. 8:1993;487-490.
12. Zhuang SM, Shvarts A, Jochemsen AG, van Oorschot AA, van der Eb AJ, Noteborn MH. Differential sensitivity to Ad5 E1B-21kD and Bcl-2 proteins of apoptin-induced versus p53-induced apoptosis. Carcinogenesis. 16:1995;2939-2944.
13. Roemer K, Mueller-Lantzsch N. p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis. Oncogene. 12:1996;2069-2079.
14. Mitry RR, Sarraf CE, Wu CG, Pignatelli M, Habib NA. Wildtype p53 induces apoptosis in Hep3B through up-regulation of bax expression. Lab Invest. 77:1997;369-378.
15. Friedman SL, Shaulian E, Littlewood T, Resnitzky D, Oren M. Resistance to p53-mediated growth arrest and apoptosis in Hep3B hepatoma cells. Oncogene. 15:1997;63-70.
16. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene - two products - two pathways. Trends Biochem Sci. 23:1998;291-296.
17. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512.
18. Inagaki M, Moustakas A, Lin HY, Lodish HF, Carr BI. Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA. Proc Natl Acad Sci USA. 90:1997;5359-5363.
19. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, et al. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J. 7:1993;1407-1413.
20. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62:1990;671-680.
21. Rouault J-P, Falette N, Guehenneux F, Guillot C, Rimokh R, Wang Q, et al. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet. 14:1996;482-486.
22. Ponchel F, Puisieux A, Tabone E, Michot J-P, Froschl G, Morel A-P, et al. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res. 54:1994;2064-2068.
23. Legros Y, Meyer A, Ory K, Soussi T. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene. 9:1994;3689-3694.
24. Shew JY, Lin BT, Chen PL, Tseng BY, Yang-Feng TL, Lee WH. C-terminal truncation of the retinoblastoma gene product leads to functional inactivation. Proc Natl Acad Sci USA. 87:1990;6-10.
25. INK4a. Mol Carcinogen. 16:1996;53-60.
26. Guan K-L, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, et al. Growth suppression by p18, a p16INK4/MTS1- and p15INK4b/MTS2-related CDK6 inhibitor, correlates with wildtype pRb function. Genes Dev. 8:1994;2939-2952.
27. Koh J, Enders GH, Dyntacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature. 375:1995;506-510.
28. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma protein-dependent cell cycle inhibition by the tumor suppressor p16. Nature. 375:1995;503-506.
29. Medema RH, Herrera RE, Lam F, Weinberg RA. Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA. 92:1995;6289-6293.
30. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12:1998;2245-2262.
31. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 352:1991;345-347.
32. Zhao J, Dynlacht B, Imai T, Hori T, Harlow E. Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes Dev. 12:1998;456-461.
33. Lukas J, Herzinger T, Hansen K, Moroni MC, Resnitzky D, Helin K, et al. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev. 11:1997;1479-1492.
34. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science. 257:1992;1958-1961.
35. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51:1991;5520-5525.